Table 4.

Associations between betaPV type-specific seropositivity and SCC

N = 1,311, n (%)Person yearsNumber of participants with SCC (%)Incidence rate/100,000/person yearsAdjusted HRa
HPV5
 Absent1,174 (90)12,344136 (12)1,1021.0
 Present137 (10)1,27814 (10)1,0951.0 (0.5–1.7)
HPV8
 Absent888 (68)9,32995 (11)1,0181.0
 Present423 (32)4,29355 (13)1,2811.1 (0.8–1.5)
HPV9
 Absent1,092 (83)11,387129 (12)1,1331.0
 Present219 (17)2,23521 (10)9400.7 (0.5–1.2)
HPV15
 Absent1,002 (76)10,522112 (11)1,0641.0
 Present309 (24)3,10038 (12)1,2261.0 (0.7–1.5)
HPV20
 Absent1,131 (86)11,895133 (12)1,1181.0
 Present180 (14)1,72717 (9)9840.6 (0.3–1.0)
HPV23
 Absent1,138 (87)11,973136 (12)1,1361.0
 Present173 (13)1,64914 (8)8490.7 (0.4–1.1)
HPV24
 Absent1,011 (77)11,455128 (13)1,1171.0
 Present300 (23)2,16722 (7)1,0150.8 (0.5–1.3)
HPV36
 Absent1,133 (86)11,887134 (12)1,1271.0
 Present178 (14)1,73516 (9)9220.7 (0.4–1.1)
HPV38
 Absent900 (69)9,386102 (11)1,0871.0
 Present411 (31)4,23648 (12)1,1330.9 (0.6–1.3)

aHR calculated using Cox proportional hazards model and adjusted for age and sex.